Anteris Technologies (AU:AVR) has released an update.
Anteris Technologies Ltd partners with v2vmedtech to advance their VClipTM, a novel Transcatheter Edge to Edge Repair system for mitral and tricuspid valve regurgitation, successfully completing an animal study and moving towards human trials. The VClipTM aims to improve upon current systems by addressing limitations and expanding eligibility for patient treatments. Anteris’s commitment to innovation in structural heart disease treatments is underscored by their development of the DurAVRTM, the world’s first single-piece, balloon-expandable aortic valve.
For further insights into AU:AVR stock, check out TipRanks’ Stock Analysis page.
